Evidence map›Paper›PMID 41152417›Full record

ArticleScientific reports2025

Genomic characterization and epidemiology of Mycobacterium tuberculosis lineage 2 isolates from Kazakhstan.

Dana Auganova, Sabina Atavliyeva, Nour Gharbi, Elena Zholdybayeva, Yuri Skiba, Akmaral Akisheva, Anna Tsepke, Arike Alenova, Christophe Guyeux, Thierry Wirth and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Dana AuganovaNational Center for Biotechnology, Astana, Kazakhstan.
Sabina AtavliyevaNational Center for Biotechnology, Astana, Kazakhstan.
Nour GharbiEPHE, PSL University, Paris, France.
Elena ZholdybayevaNational Center for Biotechnology, Astana, Kazakhstan.
Yuri SkibaNational Center for Biotechnology, Astana, Kazakhstan.
Akmaral AkishevaCity Center for Phthisiopulmonology of the Akimat of Astana, Astana, Kazakhstan.
Anna TsepkeCity Center for Phthisiopulmonology of the Akimat of Astana, Astana, Kazakhstan.
Arike AlenovaNational Scientific Center for Phthisiopulmonology, Almaty, Kazakhstan.
Christophe GuyeuxUniversité Bourgogne Franche-Comté (UBFC), Besançon, France.
Thierry Wirth *EPHE, PSL University, Paris, France. thierry.wirth@mnhn.fr.
Christophe Sola *IAME, INSERM, Université Paris-Cité, Université Sorbonne Paris-Nord, Paris, France. christophe.sola@universite-paris-saclay.fr.
Pavel Tarlykov *National Center for Biotechnology, Astana, Kazakhstan. tarlykov@biocenter.kz.

Funding

Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan AP19676216
6 · The paper itself

Abstract

Kazakhstan has one of the highest incidence rates of MDR-TB in the WHO European Region. However, data on the genomic diversity of circulating Mycobacterium tuberculosis strains in Kazakhstan remains limited. We performed whole-genome sequencing on 177 clinical M. tuberculosis isolates belonging to the L2/Beijing lineage, sourced from 15 regions across Kazakhstan. WGS data were analyzed using the computational genomics pipelines TB-Profiler, TB-Annotator, and MTBseq. We then carried out Bayesian analyses using the BEAST algorithm to predict the effective population size dynamics of M. tuberculosis in Kazakhstan over the last 50 years. Phenotypic drug susceptibility testing revealed a significant proportion of MDR (46.9%) and pre-XDR (14.7%) isolates. Phylogenetic analysis showed that 67.2% of M. tuberculosis L2/Beijing isolates belonged to the Central Asian outbreak (CAO) sublineage. Putative compensatory variants were detected in 89.6% of RIF-resistant CAO isolates, with rpoABC variants showing strong sublineage specificity. Furthermore, phylogenetic analysis contributed to the identification of six novel historical clusters, each characterized by distinct SNP signatures. Phylogenetic reconstruction indicated recent transmission and clonal expansion of CAO isolates. Meanwhile, Bayesian skyline analysis revealed a marked increase in the effective population size of Mtb. This study used genomic characterization to show that the CAO sublineage of M. tuberculosis lineage 2 has been highly successful during the MDR-TB epidemic in Kazakhstan, which has coincided with major economic fluctuations.

Indexed as

Genome, BacterialMycobacterium tuberculosisTuberculosis, Multidrug-ResistantAdultAntitubercular AgentsBayes TheoremDrug Resistance, Multiple, BacterialFemaleGenomicsHumansKazakhstanMaleMicrobial Sensitivity TestsPhylogenyPolymorphism, Single NucleotideWhole Genome SequencingAntitubercular AgentsDrug resistanceKazakhstanLineage 2Mycobacterium tuberculosisWhole-genome sequencing

Identifiers

PMID41152417
PMCPMC12568924

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.